Testing early treatment to help control asthma and prevent attacks

This trial tests a medication called dupilumab to see if it can help people with a specific type of asthma achieve remission—meaning their asthma is well-controlled and they have fewer attacks. The study targets people who show signs of high type-2 inflammation in their blood and lungs, have had at least one serious asthma attack in the past two years, and are already taking medium-to-high dose inhaled steroids. Half the participants will receive this medication, and half will receive a placebo (inactive treatment), while both groups continue their regular asthma care.

Doctors have learned that the new treatment works best when started early, before asthma becomes very severe and causes permanent damage to the lungs. This study aims to test whether giving this medication to people at high risk of serious attacks—before they meet current criteria for biological treatment—can help them achieve better control and prevent their asthma from getting worse.